US Patent 12,576,253: Scope, Claims, and US Patent Landscape for an Intravesical Mini-Tablet Delivery Device
US Patent 12,576,253 claims a catheter-free intravesical drug delivery device built around two integrally formed tubes (silicone or polymeric), a nitinol elastic retention frame, and a reservoir containing multiple “mini-tablets” that dissolve after placement in the bladder and release drug via osmotic pressure and/or diffusion through a tube wall or a sidewall aperture. The independent scope is constrained tightly around (1) mechanical deployment and anti-voiding retention behavior driven by a specific arch retention geometry and a measured low acting force limit, and (2) drug payload form including mini-tablets with high drug loading (at least 50% by weight in some dependent claims; at least 75% by weight in the silicone/gemcitabine embodiment) and defined drug classes (gemcitabine/salts; “kinase inhibitor” with explicit FGFR3-selective tyrosine kinase inhibitor language).
What is the core claimed device architecture?
Claim 1 (silicone-tube/gemcitabine embodiment) and Claim 8/17 (polymeric-tube/kinase inhibitor embodiment(s)) share the same structural theme:
- Two integrally formed, longitudinally adjoined tubes
- “Two integrally formed silicone tubes” in Claim 1
- “Two integrally formed polymeric tubes” in Claims 8 and 17
- Two functional lumens
- One tube defines a drug reservoir lumen
- The adjacent tube defines a retention frame lumen
- Sealed reservoir ends
- Reservoir lumen has a first and opposed second end that are sealed
- A retention frame
- A nitinol elastic wire sits in the retention frame lumen
- Device body deformation
- Device is elastically deformable between:
- Retention shape (smaller profile for insertion retention)
- Deployment shape (post-insertion configuration)
- Retention shape comprises two smaller arches sharing a common larger arch
- In Claim 17, the “smaller arches overlap” on compression and then “all three of the arches resist compression” to impede collapse and voiding as bladder contracts.
How does claimed drug release work?
The release mechanism is claim-structured around osmotic pressure and diffusion pathways:
- Osmotic-driven release through a sidewall aperture (Claim 1)
- “Release ... driven by osmotic pressure ... through an aperture in a sidewall of the silicone tube”
- Diffusion-driven release through a polymeric tube wall (Claim 8)
- “Release ... driven by diffusion through a wall of the polymeric tube”
- Two-mode release options explicitly included (Claim 17)
- Release driven by either:
- (i) osmotic pressure through an aperture, or
- (ii) diffusion through the tube wall
What are the mechanical/biomechanical constraints that narrow scope?
Multiple independent and dependent claims include explicit low-force limits and retention geometry constraints:
- Maximum acting force cap
- Claims 1, 8, 17: device body exerts maximum acting force < 1 N when compressed from retention shape to a deployed compression profile with maximum dimension in any direction of 3 cm or less
- Stricter force cap variant
- Claims 3 and 10 and 18: < 1 N when compressed to 1.5 cm maximum dimension
- Retention-shape size cap
- Claims 4, 11, 19: retention shape has a maximum dimension in any direction of 6 cm or less in uncompressed state
What are the payload form constraints?
The mini-tablets are defined by drug type and loading:
- Drug loading in Claim 1 (silicone/gemcitabine)
- Mini-tablets comprise at least 75% by weight drug, remainder excipients
- Mini-tablets quantity and alignment
- Claims 2 and 9: 10 to 100 mini-tablets, aligned “in a row” in the drug reservoir lumen
- Mini-tablets excipient content
- Claims 5 and 12: excipients include lubricants and binders
- Lower bound drug loading variants
- Claim 6: at least 80% by weight drug for the gemcitabine embodiment
- Claim 13: at least 50% by weight drug for the polymeric/kinase inhibitor embodiment
- Drug identity examples embedded in claims
- Claim 1: gemcitabine or salt
- Claim 8: “kinase inhibitor” (generic) plus excipients
- Claim 16: explicit FGFR3-selective tyrosine kinase inhibitor
- Claim 20: same FGFR3-selective tyrosine kinase inhibitor in the Claim 17 line
- Claim 21: gemcitabine/salt in the Claim 17 line
Detailed claim-by-claim scope
Claim 1: The foundational combination (silicone + gemcitabine + osmotic aperture + low acting force + arch retention)
Claim 1 defines a complete package:
- Device body
- Two integrally formed silicone tubes, aligned and adjoined along a longitudinal edge
- Each tube defines one lumen:
- drug reservoir lumen
- retention frame lumen
- Reservoir lumen ends are sealed
- Mini-tablets
- Disposed in reservoir lumen
- At least 75% by weight drug, remainder excipients
- Drug is gemcitabine or salt
- Retention frame
- Elastic nitinol wire in retention frame lumen
- In vivo behavior
- Mini-tablets solubilize in vivo and release gemcitabine
- Release driven by osmotic pressure through an aperture in the silicone tube sidewall
- Mechanical deformation
- Elastically deformable between retention and deployment shape for urethral insertion
- Retention shape geometry: two smaller arches sharing a common larger arch
- Low acting force limitation
- Maximum acting force < 1 N
- Measured when compressed from retention shape to a shape with maximum dimension in any direction ≤ 3 cm
Claims 2-7: Gemcitabine-specific dependent limits
- Claim 2: 10-100 mini-tablets in a row
- Claim 3: acting force < 1 N at maximum dimension ≤ 1.5 cm when compressed
- Claim 4: retention shape max dimension ≤ 6 cm uncompressed
- Claim 5: excipients include lubricants and binders
- Claim 6: mini-tablets drug content ≥ 80% by weight
- Claim 7: reservoir lumen cylindrical
These dependent claims tighten both formulation and mechanics without changing the foundational functional architecture.
Claim 8: Polymer-tube + generic kinase inhibitor + diffusion release
Claim 8 replaces the silicone/osmotic aperture concept with polymer/diffusion:
- Device body has two integrally formed polymeric tubes
- One defines reservoir lumen, one defines retention frame lumen
- Reservoir ends sealed
- Reservoir contains mini-tablets with:
- drug: “a kinase inhibitor”
- plus excipients
- Retention frame: nitinol elastic wire
- Release:
- mini-tablets solubilize in vivo
- release kinase inhibitor driven by diffusion through a wall of the polymeric tube
- Deformation and retention geometry:
- retention shape: two smaller arches sharing a common larger arch
- Acting force cap: < 1 N at compression to max dimension ≤ 3 cm
Claims 9-15: Polymer embodiment dependent scope
- Claim 9: 10-100 mini-tablets aligned in row
- Claim 10: acting force < 1 N at max dimension ≤ 1.5 cm when compressed
- Claim 11: retention shape max dimension ≤ 6 cm uncompressed
- Claim 12: lubricants and binders in excipients
- Claim 13: mini-tablets drug content ≥ 50% by weight
- Claim 14: cylindrical reservoir lumen
- Claim 15: polymeric tube formed from “water permeable, biocompatible elastomeric material”
Claim 15 is a material-path narrowing element tied directly to diffusion viability.
- Claim 16: drug is a FGFR3-selective tyrosine kinase inhibitor
Claim 17: Dual-path release (osmotic via aperture OR diffusion via wall) + anti-collapse anti-voiding arch interaction
Claim 17 expands the release mechanism options while adding explicit retention stability behavior during urination:
- Two integrally formed polymeric tubes
- Nitinol elastic wire retention frame in retention frame lumen
- Mini-tablets containing “a drug and one or more excipients” (no drug identity at base)
- Release driven by either:
- osmotic pressure through an aperture OR
- diffusion through the tube wall
- Retention geometry:
- retention shape has two smaller arches sharing common larger arch
- “upon compression the smaller arches overlap”
- then “all three ... resist compression ... to impede collapse”
- “impede voiding ... as the bladder contracts during urination”
- Acting force cap: < 1 N at compression to max dimension ≤ 3 cm
Claims 18-21: Claim 17 dependent constraints
- Claim 18: acting force < 1 N at max dimension ≤ 1.5 cm when compressed
- Claim 19: retention shape max dimension ≤ 6 cm uncompressed
- Claim 20: drug is FGFR3-selective tyrosine kinase inhibitor
- Claim 21: drug is gemcitabine or salt
Net effect: Claim 17 is a “platform” claim that includes both gemcitabine and FGFR3 tyrosine kinase inhibitor options while keeping the mechanical anti-voiding arch behavior and dual release pathways.
Scope summary in engineering terms (what would still fall inside vs outside)
Device-in
A candidate design likely falls within the independent-claim scaffold if it has all of the following:
- Two integrally formed aligned adjoined tubes forming:
- sealed drug reservoir lumen
- retention frame lumen
- Nitinol elastic wire retention frame inside retention frame lumen
- Retention shape based on an arch system:
- two smaller arches sharing a common larger arch
- (in Claim 17) overlap of smaller arches on compression and post-overlap resistance that impedes collapse/voiding
- Mechanical force constraint:
- maximum acting force < 1 N when compressed to a ≤3 cm max dimension profile (and also dependent <1.5 cm)
- Drug delivery:
- mini-tablets solubilize in vivo
- release driven by osmotic pressure via aperture and/or diffusion through tube wall
- Drug formulation constraints:
- mini-tablet count 10-100 and alignment in row are in dependents, not all independent claim scope
- drug loading thresholds vary by claim (≥75% or ≥80% for gemcitabine; ≥50% for generic kinase inhibitor claim line)
Device-out (high-level)
Likely to fall outside if it:
- uses a different retention concept (no nitinol elastic frame in a second lumen; or no two smaller arches sharing common larger arch; or no anti-collapse overlap behavior as recited)
- replaces low acting force performance with a higher force interface that fails the <1 N limitation
- delivers drug without mini-tablets solubilizing in vivo in a sealed reservoir with the defined release physics (osmotic aperture and/or diffusion through a permeable tube wall)
- substitutes the claimed drug loading profile when those are part of the asserted dependent claim
- uses a single-lumen housing without integrally formed two-tube construction
Comparative claim coverage table (what each independent claim locks in)
| Dimension |
Claim 1 |
Claim 8 |
Claim 17 |
| Tube material |
Silicone tubes |
Polymeric tubes |
Polymeric tubes |
| Release mechanism |
Osmotic pressure through sidewall aperture |
Diffusion through polymer wall |
Osmotic through aperture OR diffusion through wall |
| Drug identity |
Gemcitabine/salt |
Kinase inhibitor (FGFR3-selective in dependent) |
Drug unspecified at base; gemcitabine/FGFR3 in dependents |
| Retention geometry |
Two smaller arches sharing larger arch |
Same |
Same + overlap and anti-collapse/anti-voiding behavior during urination |
| Retention frame |
Nitinol elastic wire |
Nitinol elastic wire |
Nitinol elastic wire |
| Mechanical constraint |
Max acting force < 1 N at ≤3 cm compression profile |
Same |
Same |
| Key formulation thresholds |
≥75% drug by weight (with excipients remainder) |
≥50% drug by weight in dependent |
No threshold at base; dependents specify gemcitabine or FGFR3 |
US patent landscape: likely competitive zones and blocking themes
A complete US landscape for “scope and claims” requires a search in USPTO databases and paid patent family tooling against the exact assignee, earliest priority, and claim construction. No such bibliographic metadata is provided here. Per the constraints, the analysis below is limited to what can be inferred from the claim language itself: the technology boundary conditions that shape who can design around it, and the most likely families that compete on either (a) intravesical controlled release platforms, or (b) drug-specific intravesical payloads.
1) Platform competitors likely keyed to the same functional triad
The claims combine:
- (i) intravesical mechanical retention and deployment via an arch-based nitinol frame,
- (ii) sealed reservoir with mini-tablets that solubilize in bladder fluid,
- (iii) controlled release physics: osmotic aperture and/or diffusion through permeable tube wall.
Competitors will typically try to differentiate on one or two axes:
- change tube material or reservoir closure scheme,
- replace osmotic aperture release with purely diffusion,
- use different retention geometry or frame material,
- increase or eliminate the low acting force profile in compression,
- avoid “mini-tablets in a sealed reservoir lumen” architecture by using different drug forms (e.g., gels, implants, layered matrices).
2) Drug-specific competitive zone (gemcitabine and FGFR3-selective TKIs)
- Claim 1 and Claim 21 lock gemcitabine delivery in this device architecture.
- Claim 16 and Claim 20 lock FGFR3-selective tyrosine kinase inhibitors.
In a landscape sense, there are two layers:
- Drug substance and kinase inhibitor patents (likely composition-of-matter and crystalline/polymorph or method-of-use protections).
- Intravesical device delivery and release patents (likely covering reservoir mechanics, controlled release and retention features).
Even if a competing program has a freedom-to-operate advantage on the drug compound, the device architecture and release mechanism can still be the blocking factor. Conversely, even if the device is novel, the drug layer can still be constrained by composition-of-matter coverage.
3) Mechanical design-around pressure points
The claims hard-wire mechanical performance metrics and geometry. In practice, these create clear design-around targets:
- Force target: maximum acting force < 1 N under defined compression-to-dimension profiles (≤3 cm and dependent ≤1.5 cm).
- Retention geometry: two smaller arches sharing a common larger arch.
- Anti-collapse behavior (Claim 17): overlap of smaller arches on compression and subsequent resistance to collapse to impede voiding during urination.
Programs seeking to avoid infringement often:
- use different retention architecture (e.g., petals, spirals, umbrella-like frameworks),
- use different actuator materials,
- design for a higher compression force envelope,
- rely on bladder outlet friction alone rather than the claimed arch anti-collapse behavior.
4) Release mechanism design-around pressure points
The claim set has explicit release pathways:
- Osmotic pressure through an aperture (Claim 1; Claim 17 alternative)
- Diffusion through tube wall (Claim 8; Claim 17 alternative)
- Polymer tube material requirement in dependent Claim 15: “water permeable, biocompatible elastomeric material”
Competitors can reduce risk by:
- using purely diffusion with a different reservoir/transport mechanism,
- eliminating apertures and changing the way osmotic gradients form,
- using non-permeable structural layers that change release physics,
- changing the physical path by which mini-tablet dissolution and transport occurs.
Actionable scope implications for R&D and IP strategy
What is the effective “platform claim” coverage?
Claim 17 is the closest to a “platform” control point because it:
- keeps both osmotic and diffusion release modes in a single independent claim,
- explicitly adds anti-collapse anti-voiding behavior during urination,
- supports multiple drug payloads in dependents (gemcitabine/salt and FGFR3-selective TKIs).
From an infringement standpoint, Claim 17’s broadness comes from the dual release pathways and the generic drug-at-base language.
Where are the tighter locks?
- Claim 1 is tighter than Claim 17 on tube material (silicone), drug identity (gemcitabine), and osmotic through aperture.
- Dependent claims lock drug load fractions and mini-tablet structural constraints (10-100, row alignment, cylinder lumen).
- Dependent Claim 15 locks material class for the polymer tube in the diffusion claim family.
How to read the risk posture by development direction
- If developing gemcitabine delivery intravesically with a two-lumen nitinol retention frame and mini-tablet dissolution, risk centers on matching:
- silicone or polymer tube architecture,
- osmotic aperture vs diffusion,
- force and retention shape constraints.
- If developing FGFR3-selective kinase inhibitor intravesical delivery, the independent Claim 8 and dependent Claim 16 create a concentrated risk zone around diffusion through water-permeable elastomeric polymer tubes and the same retention geometry and mechanical constraint set.
- If pursuing a combined release mechanism (osmotic plus diffusion), Claim 17 is the most relevant independent scaffold.
Key Takeaways
- US Patent 12,576,253 claims a two-tube intravesical device with a nitinol elastic retention frame and a sealed mini-tablet drug reservoir where release occurs via osmotic aperture and/or diffusion through the tube wall.
- The independent claims are constrained by explicit mechanical deployment and retention performance: retention geometry (two smaller arches sharing a common larger arch) plus a maximum acting force < 1 N when compressed to ≤3 cm (and dependent ≤1.5 cm).
- The drug payload is not limited to a single compound across all independent scope: gemcitabine/salts and FGFR3-selective tyrosine kinase inhibitors are explicitly supported through dependent claims.
- Claim 17 is the broadest “platform-like” risk anchor because it includes both osmotic and diffusion release pathways and includes an explicit anti-collapse overlap behavior to impede voiding during urination.
FAQs
1) Does the patent require osmotic pressure release, diffusion, or both?
The independent claims cover either mechanism depending on the claim: Claim 1 is osmotic-through-aperture; Claim 8 is diffusion-through-wall; Claim 17 includes both as alternatives.
2) Is gemcitabine explicitly required for all claims?
No. Gemcitabine is explicit in Claim 1 and also appears as a dependent payload in Claim 21 under Claim 17. Claim 8 supports “kinase inhibitor” more generally (with FGFR3-selective TKIs in dependents).
3) What mechanical feature most strongly narrows the device space?
The measured “maximum acting force less than 1 N” under specified compression-to-dimension constraints, combined with the specific arch-based retention frame geometry.
4) What limits drug loading and mini-tablet form?
Gemcitabine embodiment dependents require high drug loading (at least 75% by weight in Claim 1; at least 80% in Claim 6). The kinase inhibitor embodiment has a lower bound drug loading in dependent Claim 13 (at least 50%). Excipients include lubricants and binders in multiple dependents.
5) Where is the retention stability during urination defined?
Claim 17 adds explicit overlap and anti-collapse behavior: smaller arches overlap on compression, then all three arches resist collapse to impede voiding as the bladder contracts.
References
[1] US Patent 12,576,253 (claims as provided in prompt).
